• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.

作者信息

Lissner Donata, Glauben Rainer, Allers Kristina, Sonnenberg Elena, Loddenkemper Christoph, Schneider Thomas, Siegmund Britta

机构信息

Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Department for Gastroenterology, Infectious Diseases and Rheumatology, Berlin, Germany.

PathoTres Praxis fìr Pathologie und Neuropathologie, Berlin, Germany.

出版信息

Am J Gastroenterol. 2018 Jan;113(1):146-148. doi: 10.1038/ajg.2017.395.

DOI:10.1038/ajg.2017.395
PMID:29311733
Abstract
摘要

相似文献

1
Pulmonary Manifestation of Crohn's Disease Developed Under Treatment With Vedolizumab.维得利珠单抗治疗期间出现的克罗恩病肺部表现
Am J Gastroenterol. 2018 Jan;113(1):146-148. doi: 10.1038/ajg.2017.395.
2
Vedolizumab: first global approval.维得利珠单抗：全球首次获批。
Drugs. 2014 Jul;74(11):1293-303. doi: 10.1007/s40265-014-0253-1.
3
[Current position on Vedolizumab for ulcerative colitis and Crohn's disease].[维多珠单抗治疗溃疡性结肠炎和克罗恩病的当前立场]
Z Gastroenterol. 2015 Jun;53(6):591-602. doi: 10.1055/s-0034-1399400. Epub 2015 May 27.
4
Questions and answers about the management of Crohn's disease and ulcerative colitis with vedolizumab.关于维多珠单抗治疗克罗恩病和溃疡性结肠炎的问答
Gastroenterol Hepatol. 2019 Dec;42(10):650-656. doi: 10.1016/j.gastrohep.2019.08.007. Epub 2019 Oct 18.
5
Necrobiotic Pulmonary Nodules of Crohn's Disease in a Patient Receiving Vedolizumab.接受维多珠单抗治疗的克罗恩病患者出现坏死性肺结节
Am J Respir Crit Care Med. 2019 Jan 1;199(1):e1-e2. doi: 10.1164/rccm.201806-1056IM.
6
The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.维得利珠单抗在溃疡性结肠炎和克罗恩病中的安全性：全球上市后 4 年的数据。
J Crohns Colitis. 2020 Feb 10;14(2):192-204. doi: 10.1093/ecco-jcc/jjz137.
7
Vedolizumab Induces Long-term Mucosal Healing in Patients With Crohn's Disease and Ulcerative Colitis.维多珠单抗可诱导克罗恩病和溃疡性结肠炎患者实现长期黏膜愈合。
J Crohns Colitis. 2017 Sep 1;11(9):1085-1089. doi: 10.1093/ecco-jcc/jjx048.
8
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.维得利珠单抗为活动性炎症性肠病患者提供 1 年以上的临床获益-一项前瞻性多中心观察研究。
Aliment Pharmacol Ther. 2016 Dec;44(11-12):1199-1212. doi: 10.1111/apt.13813. Epub 2016 Oct 7.
9
Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.真实世界中 vedolizumab 治疗炎症性肠病的疗效和安全性：苏格兰 vedolizumab 队列研究。
J Crohns Colitis. 2019 Sep 19;13(9):1111-1120. doi: 10.1093/ecco-jcc/jjz042.
10
Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.维多珠单抗用于溃疡性结肠炎和克罗恩病：GEMINI研究的结果及意义
Immunotherapy. 2014;6(9):963-71. doi: 10.2217/imt.14.66.

引用本文的文献

1
Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections.炎症性肠病中的肺部受累：共同途径与不良关联
J Clin Med. 2023 Oct 9;12(19):6419. doi: 10.3390/jcm12196419.
2
Cavitary lung nodules as an extraintestinal manifestation of ulcerative colitis.肺空洞性结节作为溃疡性结肠炎的一种肠外表现。
BMJ Case Rep. 2022 Sep 23;15(9):e251976. doi: 10.1136/bcr-2022-251976.
3
Case report: Eosinophilic pneumonia associated with vedolizumab therapy in a patient with ulcerative colitis.病例报告：一名溃疡性结肠炎患者使用维多珠单抗治疗后出现嗜酸性粒细胞性肺炎。

本文引用的文献

1
The α4β1 Homing Pathway Is Essential for Ileal Homing of Crohn's Disease Effector T Cells In Vivo.α4β1归巢途径对于克罗恩病效应T细胞在体内回肠归巢至关重要。
Inflamm Bowel Dis. 2017 Mar;23(3):379-391. doi: 10.1097/MIB.0000000000001029.
2
Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study.维多珠单抗诱导治疗在临床实践中用于炎症性肠病——一项全国性德国连续队列研究。
Aliment Pharmacol Ther. 2016 May;43(10):1090-102. doi: 10.1111/apt.13594. Epub 2016 Apr 1.
3
The safety of vedolizumab for ulcerative colitis and Crohn's disease.
Front Med (Lausanne). 2022 Aug 5;9:942237. doi: 10.3389/fmed.2022.942237. eCollection 2022.
4
Vedolizumab-associated diffuse interstitial lung disease in patients with ulcerative colitis: A case report.维多珠单抗相关的溃疡性结肠炎患者弥漫性间质性肺疾病：一例报告
World J Clin Cases. 2022 Feb 16;10(5):1716-1722. doi: 10.12998/wjcc.v10.i5.1716.
5
Noninfectious Pulmonary Complications Associated With Anti-Integrin Therapy: A Case Report and Systematic Review of the Literature.抗整合素治疗相关的非感染性肺部并发症：一例报告及文献系统综述
Inflamm Bowel Dis. 2022 Mar 2;28(3):479-483. doi: 10.1093/ibd/izab212.
6
Crohn's Disease with Atypical Extra-Intestinal Manifestations Developing Under Treatment with Vedolizumab.在维多珠单抗治疗期间出现非典型肠外表现的克罗恩病
Eur J Case Rep Intern Med. 2021 Feb 19;8(3):002265. doi: 10.12890/2021_002265. eCollection 2021.
7
Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.维得利珠单抗与炎症性肠病的肠外表现。
Drugs. 2021 Feb;81(3):333-347. doi: 10.1007/s40265-020-01460-3.
8
Anti-integrin therapy for inflammatory bowel disease.抗整合素治疗炎症性肠病。
World J Gastroenterol. 2018 May 7;24(17):1868-1880. doi: 10.3748/wjg.v24.i17.1868.
维多珠单抗用于溃疡性结肠炎和克罗恩病的安全性。
Gut. 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18.
4
Integrins: therapeutic targets in airway hyperresponsiveness and remodelling?整合素：气道高反应性和重塑中的治疗靶点？
Trends Pharmacol Sci. 2014 Nov;35(11):567-74. doi: 10.1016/j.tips.2014.09.006. Epub 2014 Oct 16.
5
Pulmonary diseases associated with inflammatory bowel diseases.与炎症性肠病相关的肺部疾病。
J Crohns Colitis. 2010 Oct;4(4):384-9. doi: 10.1016/j.crohns.2010.02.005. Epub 2010 Mar 17.
6
Latent pulmonary involvement in Crohn's disease: biological, functional, bronchoalveolar lavage and scintigraphic studies.克罗恩病的潜在肺部受累：生物学、功能、支气管肺泡灌洗及闪烁扫描研究
Gut. 1986 Aug;27(8):919-25. doi: 10.1136/gut.27.8.919.